BioWorld

May 27, 2004

Avanir Offering Brings $25M For Neurodex NDA, Pipeline

As it nears a new drug application filing for its second product, Avanir Pharmaceuticals Inc. priced a $25 million common stock offering that will allow it to continue development of its pipeline products. (BioWorld Today) Read More

Concurrent Pharma Takes Over Allergan's Retinoids For Equity

Brain Enzyme Pointing To Drug Strategy In Alzheimer's Disease

Plexxikon Gets $15M Investment For Diabetes Drug Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026